n n n ‘. concat(e. i18n. t(“search. voice. recognition_retry”),’n
Seven sites in Sweden, France and Spain to shape a new CDMO platform
NEW YORK, April 02, 2024–(BUSINESS WIRE)–Blue Wolf Capital Partners LLC (“Blue Wolf”), a middle-market personal equity firm targeting the commercial and healthcare sectors, announced that it has committed, subject to regulatory approvals, to obtain seven production and progression facilities: Solna, Stängnäs, Höganäs, Karlskoga, and Uppsala OTC Development in Sweden, Pessac in France and Parets in Spain, with Recipharm, a Stockholm-based contract production and progression organization (“CDMO”). .
The seven facilities have been part of Recipharm for more than a decade and have focused on the production and progression of pharmaceuticals in oral, solid, semi-solid and liquid forms. The facility serves more than 120 international consumers and has a strong track record. quality and regulatory compliance. Together, these sites will shape a new independent CDMO platform, still geared towards pharmaceutical production, which will operate a new call to be announced after the completion of the transaction.
“Blue Wolf is thrilled to have the opportunity to create a new CDMO platform with these seven European assets as a cornerstone,” said Shashank Patel, Head of Blue Wolf. “In partnership with the control and groups of those seven facilities, we look to the future to continue supplying world-class production functions and progress our partners to deliver the highest quality pharmaceuticals to patients around the world. “
Greg Behar, CEO of Recipharm, said: “We are very pleased that Blue Wolf has committed to sourcing seven of our OSD sites, marking a vital milestone for both organisations. I am confident that Blue Wolf will continue to elevate service and organizational excellence to gain advantages for consumers and patients. “By consolidating our network of locations, we are expanding our focus on new chemical entities (NCEs), medium to high potency drugs, and proprietary drugs in the oral solids testing sector. This strategic divestiture aligns with our overall vision of emerging as the CDMO of choice for our consumers and patients. I make my wishes bigger, more productive, for all of our colleagues as they embark on this new adventure to those seven sites.
Terms of the deal were revealed. The transaction is expected to close in the fourth quarter of 2024, subject to standard regulatory approvals.
About Blue Wolf Capital Partners
Blue Wolf Capital Partners LLC is a private equity firm focused on price investments in middle-market corporations in the commercial and healthcare sectors. The company’s built-in team of investment professionals and experienced operating executives work collaboratively to drive profitability by driving transformational replacement by leveraging its operational capabilities. and strategic expertise. Blue Wolf seeks to invest in corporations that have pricing catalysts that involve organizational transformation, complex human capital or union issues, a significant government presence, or the ability to use ESG-based strategies. For more information, visit www. bluewolfcapital . com.
About Récipharm
Recipharm is a leading production and contract progression organization (CDMO) in the pharmaceutical industry employing more than 7,400 employees. Recipharm offers centers for the manufacture of pharmaceuticals in dosage forms, the production of tissues for clinical trials and APIs, the progression of pharmaceuticals, and the development and manufacture of medical devices. Recipharm manufactures several hundred other consumer products, from giant pharmaceutical corporations to small studios and development corporations. The company operates development and production facilities in France, Germany, India, Israel, Italy, Portugal and Spain. , Sweden, the United Kingdom, and the United States. It is headquartered in Stockholm, Sweden.
To learn more about Recipharm and our services, visit www. recipharm. com
See the businesswire. com edition: https://www. businesswire. com/news/home/20240402076935/en/
Contactos
Kate SpazianiDirector, Government Affairs & Communications, Blue Wolf Capital Partnerskate@bluewolfcapital. com Sam ReinhardtVice President, Strategy Groups mondialereinhardt@globalstrategygroup. com 212-392-5270Guenaelle HollowayHead of comunicación,Guenaelle. Holloway@Recipharm. com